Kornimate/medical-research-clean huggingface dataset:
evaluation of patients who underwent sleeve gastrectomy with jejunoileal anastomosis for the treatment of morbid obesity

Conditions: Sleeve Gastrectomy With Jejunoileal Anastomosis

Summary: laparoscopic sleeve gastrectomy operations performed for morbid obesity are among the most common methods in the world. gastric or intestinal bypass surgery with or without sleeve gastrectomy is thought to be more effective in controlling both weight loss and metabolic diseases. for this purpose, roux-en-y gastric bypass, transit bipartition, duodenal switch, jejunoileal bypass are performed. the aim of this study was to evaluate the effects of jejunoileal bypass surgery on weight loss and metabolic diseases in patients with sleeve gastrectomy.

bariatric surgery results in more and more long-term weight loss than traditional treatment in moderate and severe obesity. due to morbid obesity, jejunoileal bypass has been applied since 1970. laparoscopic sleeve gastrectomy and jejunoileal anastomosis are among the rare techniques described in 2012. there are few studies on this technique. between 2015 and 2018, jejunoileal bypass operations with laparoscopic sleeve gastrectomy for morbid obesity will be evaluated in inonu university gastroenterology surgery clinic. the patients' age, gender, body mass index, weight loss in follow-up periods, whether there is back weight gain, the effects on metabolic diseases, early and late complications will be evaluated.

Eligibility criteria:
inclusion criteria:all patients who underwent the sleeve gastrectomy with jejunoileal bypass between 2015-2018 for the treatment morbid obesity exclusion criteria:other operations for morbid obesity except sleeve gastrectomy with jejunoileal bypass

Keywords: obesity, diabetes mellitus, bariatric surgery
study the effect of probiotics combined with bismuth quadruple rescue therapy on h pylori infective patients

Conditions: Helicobacter Pylori Infection

Summary: retrospectivly follow-up the outpatients for h pylori eradication failures more than 2 times in the digestive department of changhai hospital from 2015-2017,analyse the eradication rates and adverse effects of the therapy with 2w's compound lactobacillus acidophilus followed by 10d's bismuth, furazolidone, tetracycline contained quadruple scheme.

h pylori infection rate has been up to half of the world population. h pylori infection is associated with various diseases, especially gastric cancer. with the increasingly resistant to antibiotics,the eradication rate has decreased a lot with traditional triple therapy. exploring a valid scheem for patients who have failed multiple times is important. probiotics can improve gastrointestinal microenvironment, then release the adverse effects during the eradication process.additionally,there is also a lot evidence that probiotics can inhibit h plori，but still controversially. there is a low resistant rate about furazolidone and tetracycline. in this study investigators observe the efficacy of the therapy 2w's compound lactobacillus acidophilus followed by 10d's bismuth, furazolidone, tetracycline contained quadruple scheme on patients who have failed more than 2 times. 4 to 6 weeks after the therapy, if urea breath test (ubt) is nedative which means eradicating h plori successfully.

Eligibility criteria:
inclusion criteria: * h pylori eradication had failed more than 2 times * patients had never used furazolone and tetracycline * the age varied from 18 to 80 years old exclusion criteria: * h pylori initial eradication or had failed only 1 time * the age was lower than 18,or higher than 80 years old * patients who had serious heart pulmonary disease ,live renal disease, or any cancers * pregnant women

Keywords: helicobacter pylori eradication
maintenance therapy of narrow-band uv-b therapy in patients with vitiligo

Conditions: Phototherapy; Vitiligo; Maintenance Therapy; Narrow-band UV-B

Summary: although vitiligo is difficult to cure, recurrences are frequent after treatment, and many patients suffer from concerns about recurrence as well as disease. psoriasis, another indication for ultraviolet radiation treatment, has been established that it can safely and effectively reduce the recurrence of psoriasis through monthly maintenance therapy. the aim of this study was to evaluate the efficacy of narrow-band uv-b therapy for the prevention of relapse in vitiligo.

for a total period of 12 months, perform narrow-band uv-b treatment once a month. check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months. an independent evaluator will obtain the score of vitiligo area (vitiligo extent score) from comparing clinical photographs of before registration and after the clinical trial, and judge whether vitiligo is recurred. this study is a randomized controlled trial, and the investigators plan to compare the recurrence rates of the experimental and control groups using the chi-squared test.

Eligibility criteria:
inclusion criteria: 1. patients with age of 19 years or older 2. patients of generalized vitiligo with lesions on the trunk 3. patients who had treated with narrow-band uv-b therapy previously and achieved more than 75% lesion improvement 4. patients who voluntarily agreed to participate in the study exclusion criteria: 1. patients under the age of 19 2. patients with localized vitiligo and segmental vitiligo 3. patients who are in a state of physical or mental impairment to perform treatment or pregnant 4. patients with spreading of vitiligo lesions 5. patients who do not want to do thie study or who refuse to write a consent form 6. any other person deemed unsuitable for the examination at the discretion of the examiner
urinary tract infection in patients with chronic kidney disease

Conditions: Urinary Tract Infections; Chronic Kidney Diseases

Summary: this study aims to investigate the etiology and associated risk factors for uti in egyptian chronic kidney disease patients. in addition, to identify the isolated micro-organisms and their sensitivity patterns for better anticipation of treatment regimen.

chronic kidney disease (ckd) patients are at higher risk of urinary tract infections (uti), as ckd is a state of chronic inflammation, metabolic disturbance and impaired immunocompetence. moreover, patient with ckd are usually of advanced age and suffer from other comorbidities such as diabetes, hypertension, obesity, and cardiovascular diseases, which also add to their risk of infection. uti comprises heterogeneous conditions ranging from mild cystitis, easily treated with oral antibiotics, to life-threatening sepsis and multiple organ failure. there is scarce information about risk factors of recurrence of uti and infection with multidrug-resistant organisms in the egyptian population.

Eligibility criteria:
inclusion criteria: 1. males and non-pregnant females aged ≥ 18 years old 2. patients with ckd stages (g1 to g4) 3. patients diagnosed with uti due to urine culture exclusion criteria: 1. non-ckd patients 2. pregnant females 3. ckd patients on immunosuppressant agents 4. esrd patients on hemodialysis 5. patients with structural abnormalities which make them liable to frequent uti

Keywords: urinary tract infection chronic kidney disease uti ckd
dexmedetomidine on pediatric heart operation

Conditions: Acute Renal Injury

Summary: we hypothized dexmedetomidine could reduce the reduction of renal function after cardiopulmonary bypass weaning in pediatric patients

dexmedetomidine, a2-adrenoreceptor agonist has been used for sedation or hemodynamic stability for operative procedure. it had been already reported that dexmedetomidine reduce the impairment of renal functon after cardiac operation in adult. we hypothized dexmedetomidine could reduce the reduction of renal function after cardiopulmonary bypass weaning in pediatric patients

Eligibility criteria:
inclusion criteria: * 1-6yr pediatric cardiac patients exclusion criteria: * previous renal dysfunction
study of a phenylalanine restricted diet during pregnancy to prevent symptoms in offspring of patients with phenylketonuria

Conditions: Phenylketonuria

Summary: objectives: i. assess the impact of a phenylalanine restricted diet during pregnancy on symptoms in offspring of patients with phenylketonuria.

protocol outline: this is a multicenter study. patients receive a phenylalanine restricted diet based on a medical food such as phenyl-free, lofenalac, pku 3, or maximum xp (may be supplemented with tyrosine as needed) to achieve a target blood phenylalanine level of 2-6 mg/dl. the diet begins approximately 3 months prior to conception and continues until delivery of the baby. patients are evaluated once a month before conception and weekly during pregnancy. patients also undergo sonographic examination at 8, 20, 28, and 34 weeks gestation. at birth, the cord blood is evaluated for plasma amino acids. if the baby is found to have an elevated phenylalanine level, blood and urine are obtained to determine the baby's genetic status. phenylalanine and tyrosine levels are checked in the baby daily for three days after birth. the baby is followed for physical and mental development at 3 and 6 months and then annually thereafter.

Eligibility criteria:
* women with diagnosis of phenylketonuria who are planning on becoming pregnant slightly elevated phenylalanine level (hyperphe variant) allowed

Keywords: inborn errors of metabolism phenylketonuria rare disease
management of postoperative pain in france: a prospective national study

Conditions: Pain

Summary: managing postoperative pain is an ongoing challenge. therefore, frequent surveys are needed to constantly evaluate and improve perioperative pain care. the french reference audit was published in 2008. ten years later, the french algosfar survey of 70 centres and 3,315 patients highlighted a clear improvement in practices. however, these data have never been published in a referenced journal due to significant methodological biases. in 2024, we do not have recent french data based on rigorous methodology in the field of postoperative pain management. the objective of this study is to reassess postoperative pain management in france. this is a prospective national survey. the proposed methodology will make it possible to provide a relevant snapshot of the practices and quality of care. secondarily, areas for improvement can be identified and these results will also help in the drafting of future recommendations. 100 centres representative of the french map of surgical centres will be contacted. inclusions will take place over 2 days, identical for all centres. all patients eligible for inclusion during this period will be included.


Eligibility criteria:
inclusion criteria: * adult patients benefiting of a scheduled surgery during the inclusion period in a participating centre. exclusion criteria: * patients under 18 years old * patient's refusal * patients deprived of liberty * patients undergoing intracranial neurosurgery or cardiac surgery * expected surgery duration \< 30 minutes * urgent surgery

Keywords: postoperative pain
connect lung outcomes with bronchodilator use

Conditions: Chronic Obstructive Pulmonary Disease; Asthma

Summary: to determine the accuracy of the respimetrix flow-volume monitoring device in measuring the patient's inspiratory capacity as compared to gold-standard measurements of inspiratory capacity on pulmonary function testing. accuracy will be assessed before and after (a) pulmonary function testing and before and after (b) the administration of an inhaled bronchodilator medication.

1. specific aim #1: compare the performance of the flow-volume test device to standard pulmonary function measurements. the investigators hypothesize that measurements of inspiratory capacity with the respimetrix test device will: a. accurately measure the inspiratory capacity as assessed on standard pulmonary function tests, and will b. correlate with other measures of pulmonary function including spirometry (vital capacity, forced expiratory volume in 1 second) and lung volumes (total lung capacity, functional residual capacity and residual volume). 2. specific aim #2: examine the ability of the flow-volume test device to track changes in standard pulmonary function measurements after the administration of an inhaled bronchodilator. the investigators hypothesize that the respimetrix test device will: a. accurately measure changes in inspiratory capacity in response to a standard dose of a short acting inhaled beta-agonist (4 puffs albuterol), b. correlate with immediate changes in pulmonary function parameters including spirometry (vital capacity, forced expiratory volume in 1 second) and lung volumes (total lung capacity, functional residual capacity and residual volume).

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older who are being seen in the pulmonary clinic including asthma and chronic obstructive pulmonary disease (copd) patients. * patients must be willing and able to provide informed consent to participate in the study. * patients must be able to use a metered dose inhaler. exclusion criteria: * contraindication to inhaler use * tracheostomy * incapacitating disability that interferes with the use of the inhaler or execution of the protocol * unable to understand informed consent (e.g., non-english speakers)
electrical impedance tomography measurements during apnea test in patients with suspected brain death

Conditions: Brain Death

Summary: apnea testing is the final decisive examination in the strictly regulated process of brain death assessment. there is no standardized method found in the literature for apnea testing except for the inspection of possible spontaneous chest movements. in addition, the test itself lasts for several minutes leading to the collapse of the lungs. electrical impedance tomography (eit) is a non-invasive, real-time monitoring technique, which is suitable for detecting changes in lung volumes during ventilation. with its help, one can examine the spontaneous initiation of inspiration, the development of atelectasis and the reopening of collapsed regions by mechanical ventilation. furthermore, the apnea test provides for analysing the effect of changes in pulmonary perfusion on impedance in the absence of noise generated by ventilation.

the aim of the study is to assess the eligibility of electrical impedance monitoring for the detection of possible spontaneous initiations of inspiration during apnea test in patients with suspected brain death. the study could contribute to the opening of new areas in the clinical use of the electrical impedance device. an additional aim is to observe the collapse and the reopening by recruitment manoeuvers of different pulmonary regions.

Eligibility criteria:
inclusion criteria: * patients with suspected brain death undergoing apnea test for detecting the absence of spontaneous breathing exclusion criteria: * age under 18 * pregnancy * pulmonectomy, lung resection in the past medical history * clinically end stage chronic obstructive pulmonary disease (copd) * severe hemodynamic instability (vasopressor refractory shock) * severe bullous emphysema and/or spontaneous pneumothorax in the past medical history * chest drainage in situ due to pneumothorax and/or bronchopleural fistula

Keywords: apnea testing electrical impedance tomography
telerehabilitation in coronary heart disease

Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)); Myocardial Infarction; Percutaneous Transluminal Cutting Balloon Angioplasty of Popliteal Vein Using Fluoroscopic Guidance

Summary: cardiovascular diseases are the main cause of death worldwide. aerobic fitness is related to long-term survival and a reduction in mortality and recurrent nonfatal myocardial infarction in subjects with cardiovascular disease. however, the majority of cardiac patients do not engage in enough physical activity to obtain benefits or in the long-term struggle to maintain a physically active lifestyle. there is a need for innovative rehabilitation methods aiming at increasing longer-term adherence and hence more sustained effects on health related physical fitness. one strategy might be the use of home-based training in combination of telemonitoring guidance. therefore, the main objective of this randomized controlled clinical trial is to compare the longer-term (=1 year) effects of a 3-month supervised center-based rehabilitation program with a patient-tailored home-based cardiac rehabilitation program with telemonitoring guidance in cad patients (phase iii). the primary outcome measure is physical fitness. it is hypothesized that patients randomized to a home-based training program with telemonitoring guidance will demonstrate higher levels of physical activity at one year of follow-up, resulting in higher levels of physical fitness, compared to patients who have been enrolled to the supervised center-based cardiac rehabilitation program or control group. ninety patients will be randomized to home-based training, a center-based cardiac rehabilitation program or an advice only group (= control group). assessment will be performed at baseline, immediately at completion of the intervention and at one-year of follow-up and will include measurements of exercise tolerance, cardiovascular risk factors, physical activity, muscle strength, endothelial function, health-related quality.


Eligibility criteria:
inclusion criteria: * patients with cad (post-pci, post-mi, post-cabg) * patients on optimal medical treatment and stable with regard to symptoms and pharmacotherapy for at least 6 weeks * patients have successfully completed the 3 month ambulatory cardiac rehabilitation in hospital program * 39 yrs \< age \< 76 years * access to internet facilities or pc at home exclusion criteria: * significant undercurrent illness last 6 weeks * known severe ventricular arrhythmia with functional or prognostic significance; significant myocardial ischemia, hemodynamic deterioration or exercise-induced arrhythmia at screening or heart disease that limits exercise * co-morbidity that may significantly influence one-year prognosis * functional of mental disability that may limit exercise
adult patient outcomes after spine surgery with fibergraft bg putty/viper prime

Conditions: Spondylolisthesis, Lumbar Region; Spinal Trauma with Neurological Deficit; Degeneration of Lumbar Intervertebral Disc

Summary: the viper prime/expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. the fibergraft bioactive glass (bg) is engineered to mimic the body's natural bone healing process. while previous studies have compared the use of viper prime/expedium spine system in minimally invasive and open surgeries, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to fibergraft. we aim to recruit patients with degenerative disc disease, spondylolisthesis, trauma, and/or pseudarthrosis who require spine surgery under standard of care and use these implants. we will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. have a radiograph-based diagnosis of degenerative disc disease, spondylolisthesis, spinal trauma (i.e., fracture or dislocation), spinal stenosis, or deformity (i.e., scoliosis, kyphosis, and/or lordosis), spinal tumor, or pseudoarthrosis/failed fusion. 3. pathology of the thoracolumbar or sacral spine. 4. patients requiring fusion of 1-3 levels 5. patients receiving the surgery/devices as standard of care prescribed by the treating physician. exclusion criteria: 1. patients \< 18 years 2. patients with a cervical spine pathology 3. patients with spinal tumors 4. patients with bone density (dexa) scores \< 2.0 will be excluded. 5. current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded. 6. patients with a bmi \> 40kg/m2 7. patients requiring fusion for more than 3 levels will be excluded
safety and immune response study of gsk biologicals' influenza virus vaccine 1388442a compared with fluarix

Conditions: Influenza

Summary: the purpose of the study is to compare the safety of \& immune response to a single dose of gsk biologicals' cell-culture based influenza vaccine 138842a with that of a us licensed, egg-based trivalent influenza vaccine \[fluarix\] in healthy adults.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol * a male or non-pregnant, non-lactating female between 18 and 49 years of age at the time of vaccination * access to a telephone for scheduled follow-up telephone contacts * ability to provide written informed consent * healthy subjects as established by medical history and physical examination before entering into the study * if the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination and continue such precautions for 2 months after receipt of the study vaccine. all women will have a pregnancy test on the day of vaccination. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period * receipt of systemic glucocorticoids within 30 days of study enrollment * administration of immunosuppressant, cytotoxic, or other immune-modifying drugs (other than glucocorticoids) or irradiation within 6 months prior to study enrollment or planned administration during the study period * administration of immunoglobulins and/or blood products within 3 months prior to study enrollment or planned administration during the study period * previous vaccination against influenza (2007-2008 influenza season) * history of anaphylactic or other allergic reaction to influenza vaccine, any other vaccine, or any vaccine component or excipient * history of guillain-barre syndrome (gbs) * acute disease, febrile illness, or upper respiratory infection at screening. * history of splenectomy * any confirmed or suspected, acquired, congenital, or hereditary immunodeficiency or immunosuppressive condition (including human immunodeficiency virus \[hiv\]) based on medical history and physical examination * acquired or congenital coagulation disorders or known thrombocytopenia * current treatment with warfarin or heparin derivatives * known use of an analgesic or antipyretic medication within 12 hours prior to treatment for the purposes of prophylaxis of adverse events * any medical condition for which the us advisory committee on immunization practices recommends vaccination against influenza

Keywords: cell culture safety influenza humans adults immunogenicity influenza vaccine vaccine